AstraZeneca Statistics
Share Statistics
AstraZeneca has 3.10B shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 3.10B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.10B |
| Failed to Deliver (FTD) Shares | 263.32K |
| FTD / Avg. Volume | 4.91% |
Short Selling Information
The latest short interest is 4.03M, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 4.03M |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.13% |
| Short Ratio (days to cover) | 1.3 |
Valuation Ratios
The PE ratio is 35.42 and the forward PE ratio is 11.87. AstraZeneca's PEG ratio is 0.12.
| PE Ratio | 35.42 |
| Forward PE | 11.87 |
| PS Ratio | 4.6 |
| Forward PS | 3.7 |
| PB Ratio | 5.39 |
| P/FCF Ratio | 32.12 |
| PEG Ratio | 0.12 |
Enterprise Valuation
AstraZeneca has an Enterprise Value (EV) of 233.18B.
| EV / Earnings | 39.16 |
| EV / Sales | 5.09 |
| EV / EBITDA | 17.37 |
| EV / EBIT | 28.46 |
| EV / FCF | 35.51 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.7.
| Current Ratio | 0.82 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.7 |
| Total Debt / Capitalization | 41.26 |
| Cash Flow / Debt | 0.38 |
| Interest Coverage | 5.16 |
Financial Efficiency
Return on equity (ROE) is 0.15% and return on capital (ROIC) is 10.44%.
| Return on Equity (ROE) | 0.15% |
| Return on Assets (ROA) | 0.06% |
| Return on Capital (ROIC) | 10.44% |
| Revenue Per Employee | 509.58K |
| Profits Per Employee | 66.24K |
| Employee Count | 89.90K |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | 938.00M |
| Effective Tax Rate | 0.14 |
Stock Price Statistics
The stock price has increased by 2.75% in the last 52 weeks. The beta is 0.18, so AstraZeneca's price volatility has been higher than the market average.
| Beta | 0.18 |
| 52-Week Price Change | 2.75% |
| 50-Day Moving Average | 70.61 |
| 200-Day Moving Average | 74.92 |
| Relative Strength Index (RSI) | 45.41 |
| Average Volume (20 Days) | 5.36M |
Income Statement
In the last 12 months, AstraZeneca had revenue of $45.81B and earned $5.96B in profits. Earnings per share was $1.92.
| Revenue | 45.81B |
| Gross Profit | 37.77B |
| Operating Income | 8.19B |
| Net Income | 5.96B |
| EBITDA | 13.42B |
| EBIT | 8.19B |
| Earnings Per Share (EPS) | 1.92 |
Balance Sheet
The company has $5.84B in cash and $28.62B in debt, giving a net cash position of -$22.78B.
| Cash & Cash Equivalents | 5.84B |
| Total Debt | 28.62B |
| Net Cash | -22.78B |
| Retained Earnings | 4.52B |
| Total Assets | 104.92B |
| Working Capital | -1.77B |
Cash Flow
In the last 12 months, operating cash flow was $10.35B and capital expenditures -$3.78B, giving a free cash flow of $6.57B.
| Operating Cash Flow | 10.35B |
| Capital Expenditures | -3.78B |
| Free Cash Flow | 6.57B |
| FCF Per Share | 4.2 |
Margins
Gross margin is 82.45%, with operating and profit margins of 17.88% and 13%.
| Gross Margin | 82.45% |
| Operating Margin | 17.88% |
| Pretax Margin | 15.06% |
| Profit Margin | 13% |
| EBITDA Margin | 29.3% |
| EBIT Margin | 17.88% |
| FCF Margin | 14.33% |
Dividends & Yields
AZN pays an annual dividend of $0.98, which amounts to a dividend yield of 1.46%.
| Dividend Per Share | $0.98 |
| Dividend Yield | 1.46% |
| Dividend Growth (YoY) | 5.38% |
| Payout Ratio | 47.12% |
| Earnings Yield | 2.88% |
| FCF Yield | 3.18% |
Analyst Forecast
The average price target for AZN is $85, which is 27.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $85 |
| Price Target Difference | 27.7% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Jul 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.76 |
| Piotroski F-Score | 6 |